Biomarkers in Severe Asthma

被引:46
作者
Wan, Xiao Chloe
Woodruff, Prescott G. [1 ]
机构
[1] Univ Calif San Francisco, Dept Med, Div Pulm Crit Care Sleep & Allergy, 513 Parnassus Ave,HSE 1305, San Francisco, CA 94143 USA
关键词
Severe asthma; Biomarker; Eosinophil; Periostin; Exhaled nitric oxide; Endotype; SPUTUM EOSINOPHIL COUNTS; EXHALED NITRIC-OXIDE; DOUBLE-BLIND; MONOCLONAL-ANTIBODY; SERUM PERIOSTIN; AIRWAY INFLAMMATION; CLUSTER-ANALYSIS; CELL COUNTS; EXACERBATIONS; MEPOLIZUMAB;
D O I
10.1016/j.iac.2016.03.004
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Biomarkers have been critical for studies of disease pathogenesis and the development of new therapies in severe asthma. In particular, biomarkers of type 2 inflammation have proven valuable for endotyping and targeting new biological agents. Because of these successes in understanding and marking type 2 inflammation, lack of knowledge regarding non-type 2 inflammatory mechanisms in asthma will soon be the major obstacle to the development of new treatments and management strategies in severe asthma. Biomarkers can play a role in these investigations as well by providing insight into the underlying biology in human studies of patients with severe asthma.
引用
收藏
页码:547 / +
页数:12
相关论文
共 87 条
[1]   ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005 [J].
American Thoracic Society ;
European Respiratory Society .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 171 (08) :912-930
[2]   New and future strategies to improve asthma control in children [J].
Anderson, William C., III ;
Szefler, Stanley J. .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 136 (04) :848-859
[3]   Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].
Atkinson, AJ ;
Colburn, WA ;
DeGruttola, VG ;
DeMets, DL ;
Downing, GJ ;
Hoth, DF ;
Oates, JA ;
Peck, CC ;
Schooley, RT ;
Spilker, BA ;
Woodcock, J ;
Zeger, SL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95
[4]   Adiponectin in Asthma and Obesity: Protective Agent or Risk Factor for More Severe Disease? [J].
Azambuja, Renato de Lima ;
da Costa Santos Azambuja, Layla Salomao Eulalio ;
Costa, Claudia ;
Rufino, Rogerio .
LUNG, 2015, 193 (05) :749-755
[5]   Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial [J].
Baeten, Dominique ;
Baraliakos, Xenofon ;
Braun, Juergen ;
Sieper, Joachim ;
Emery, Paul ;
van der Heijde, Desiree ;
McInnes, Iain ;
van Laar, Jacob M. ;
Landewe, Robert ;
Wordsworth, Paul ;
Wollenhaupt, Juergen ;
Kellner, Herbert ;
Paramarta, Jacqueline ;
Wei, Jiawei ;
Brachat, Arndt ;
Bek, Stephan ;
Laurent, Didier ;
Li, Yali ;
Wang, Ying A. ;
Bertolino, Arthur P. ;
Gsteiger, Sandro ;
Wright, Andrew M. ;
Hueber, Wolfgang .
LANCET, 2013, 382 (9906) :1705-1713
[6]   Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma [J].
Bel, Elisabeth H. ;
Wenzel, Sally E. ;
Thompson, Philip J. ;
Prazma, Charlene M. ;
Keene, Oliver N. ;
Yancey, Steven W. ;
Ortega, Hector G. ;
Pavord, Ian D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (13) :1189-1197
[7]   Induced sputum cell counts in healthy adults [J].
Belda, J ;
Leigh, R ;
Parameswaran, K ;
O'Byrne, PM ;
Sears, MR ;
Hargreave, FE .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 161 (02) :475-478
[8]   Periostin facilitates eosinophil tissue infiltration in allergic lung and esophageal responses [J].
Blanchard, C. ;
Mingler, M. K. ;
McBride, M. ;
Putnam, P. E. ;
Collins, M. H. ;
Chang, G. ;
Stringer, K. ;
Abonia, J. P. ;
Molkentin, J. D. ;
Rothenberg, M. E. .
MUCOSAL IMMUNOLOGY, 2008, 1 (04) :289-296
[9]   Pediatric severe asthma is characterized by eosinophilia and remodeling without TH2 cytokines [J].
Bossley, Cara J. ;
Fleming, Louise ;
Gupta, Atul ;
Regamey, Nicolas ;
Frith, Jennifer ;
Oates, Timothy ;
Tsartsali, Lemonia ;
Lloyd, Clare M. ;
Bush, Andrew ;
Saglani, Sejal .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2012, 129 (04) :974-U469
[10]   Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial [J].
Brightling, Christopher E. ;
Chanez, Pascal ;
Leigh, Richard ;
O'Byrne, Paul M. ;
Korn, Stephanie ;
She, Dewei ;
May, Richard D. ;
Streicher, Katie ;
Ranade, Koustubh ;
Piper, Edward .
LANCET RESPIRATORY MEDICINE, 2015, 3 (09) :692-701